Table 1:
Characteristics of the study sample
| All patients | ACC | Bivariate analyses with ACC | ||||
|---|---|---|---|---|---|---|
| N=524 | Yes (N=28) | No (N=496) | OR (95% CI) | P-value | ||
| Age, mean (SD) | 76.6 (5.2) | 77.8 (6.2) | 76.6 (5.2) | 1.04 (0.98-1.12) | 0.23 | |
| Gender | Male | 269 (51.3) | 12 (42.9) | 256 (51.6) | Reference | |
| Female | 255 (48.7) | 16 (57.1) | 240 (48.4) | 1.43 (0.67-3.09) | 0.36 | |
| Marital Status | Married | 338 (64.5) | 15 (53.6) | 322 (64.9) | Reference | |
| Other | 186 (35.6) | 13 (46.4) | 174 (35.1) | 1.62 (0.75-3.48) | 0.22 | |
| Race | White | 470 (89.7) | 21 (75.0) | 449 (90.5) | Reference | |
| Non-white | 54 (10.3) | 7 (25.0) | 47 (9.5) | 3.18 (1.29-7.89) | 0.01 | |
| Education | Some college or above | 272 (51.9) | 10 (35.7) | 262 (52.8) | Reference | 0.02d |
| High school graduate | 189 (36.1) | 10 (35.7) | 179 (36.1) | 1.46 (0.60-3.59) | 0.41 | |
| <High school | 63 (12.0) | 8 (28.6) | 55 (11.1) | 3.81 (1.44-10.09) | 0.007 | |
| Annual household incomea | >$50,000 | 163 (31.2) | 2 (7.1) | 160 (32.4) | Reference | 0.05d |
| ≤$50,000 | 257 (49.2) | 18 (64.3) | 239 (48.4) | 6.06 (1.39-26.48) | 0.02 | |
| Decline to answer | 102 (19.5) | 8 (28.6) | 95 (19.2) | 6.85 (1.43-32.93) | 0.02 | |
| Cancer typea | Breast | 68 (13.0) | 3 (10.7) | 65 (13.2) | Reference | 0.49d |
| Gastrointestinal | 123 (23.5) | 6 (21.4) | 117 (23.7) | 1.11 (0.27-4.59) | 0.88 | |
| Genitourinary | 69 (13.2) | 2 (7.1) | 67 (13.6) | 0.65 (0.11-4.00) | 0.64 | |
| Lung | 132 (25.2) | 6 (21.4) | 126 (25.5) | 1.03 (0.25-4.26) | 0.97 | |
| Other | 131 (25.1) | 11 (39.3) | 119 (24.1) | 1.99 (0.54-7.37) | 0.31 | |
| Physical performance | Impaired | 490 (93.3) | 26 (92.9) | 463 (93.4) | 0.89 (0.20-3.95) | 0.89 |
| Functional status | Impaired | 309 (59.0) | 12 (42.9) | 297 (59.9) | 0.50 (0.23-1.09) | 0.08 |
| Comorbidity | Impaired | 335 (64.0) | 17 (60.7) | 318 (64.1) | 0.87 (0.40-1.89) | 0.72 |
| Cognition | Impaired | 174 (33.2) | 7 (25.0) | 167 (33.7) | 0.66 (0.27-1.58) | 0.35 |
| Nutrition | Impaired | 315 (60.1) | 15 (53.6) | 300 (60.5) | 0.75 (0.35-1.62) | 0.47 |
| Instrumental social support | Impaired | 150 (28.6) | 15 (53.6) | 135 (27.2) | 3.09 (1.43-6.66) | 0.004 |
| Polypharmacy | Screen positive | 437 (83.4) | 20 (71.4) | 418 (84.3) | 0.47 (0.20-1.11) | 0.09 |
| Psychological health | Impaired | 131 (25.0) | 5 (17.9) | 126 (25.4) | 0.64 (0.24-1.72) | 0.37 |
| Recalled prognosisc | Completely/Mostly | 371 (71.2) | 22 (81.5) | 349 (70.7) | Reference | |
| A little/Not at all | 150 (28.8) | 5 (18.5) | 145 (29.4) | 0.55 (0.20-1.47) | 0.23 | |
| PEPPI, mean (SD) | 21.4 (3.4) | 21.7 (3.7) | 21.3 (3.4) | 1.03 (0.92-1.16) | 0.62 | |
| Adverse reaction vs. survival trade-off, mean (SD) | 2.4 (1.6) | 2.3 (1.3) | 2.3 (1.5) | 0.94 (0.73-1.22) | 0.64 | |
| Quality of life vs. survival trade-offb | Strongly agree/agree | 381 (72.9) | 18 (64.3) | 364 (73.5) | Reference | 0.39d |
| Neutral | 101 (19.3) | 6 (21.4) | 95 (19.2) | 1.27 (0.49-3.30) | 0.62 | |
| Strongly disagree/disagree | 41 (7.8) | 4 (14.3) | 36 (7.3) | 2.18 (0.70-6.78) | 0.18 | |
a
2 patients had missing data
b
1 patient had missing data
c
3 patients had missing data
d
Overall P-value
Abbreviations: ACC, absolute certainty about curability; OR, Odds Ratio; CI, Confidence Interval; PEPPI, Perceived Efficacy in Patient-Physician Interactions